Amryt Pharma Overview
Update this profile
Amryt Pharma General Information
Description
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).
Contact Information
Amryt Pharma Timeline
Financing Round Captured Employee Count Estimated Employee Growth
Want to dig into this profile?
We’ll help you find what you need
Learn more
Amryt Pharma Financials Summary
In Thousands, USD
TTM
31-Mar-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
Revenue
233,240
222,543
182,607
58,124
EBITDA
65,543
67,637
(39,143)
(42,823)
Net Income
3,046
1,000
(104,527)
(62,998)
Total Assets
786,867
816,057
536,591
527,096
Total Debt
206,463
199,183
189,351
180,090
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Amryt Pharma Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore Amryt Pharma‘s full profile, request access.
Request a free trial
Amryt Pharma Executive Team (10)
Update this profile
Name
Title
Board Seat
Contact Info
Joseph Wiley
Founder, Chief Executive Officer & Board Member
Rory Nealon
Chief Financial Officer, Finance & Chief Operating Officer, Operations
Elizabeth Jobes JD
Senior Vice President & Global Chief Compliance Officer
Kieran Rooney Ph.D
Senior Vice President & Head, Business Development
Stephen Joyce
Vice President, Global Marketing
You’re viewing 5 of 10 executive team members. Get the full list »
Amryt Pharma Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Amryt Pharma Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore Amryt Pharma‘s full profile, request access.
Request a free trial
Amryt Pharma
Acquisitions (6)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
0000000
05-Aug-2021
0000000000
00000
Drug Delivery
000000 00
0000 0000000
12-Oct-2020
0000000000
00000
Biotechnology
00000000 0000
24-Sep-2019
0000000000
00000
Biotechnology
000000 00
000000 (00000
18-Apr-2016
0000000000
000.00
Drug Discovery
Fastnet Equity
18-Apr-2016
Merger/Acquisition
000.00
Energy Exploration
You’re viewing 5 of 6 acquisitions. Get the full list »